9.14
4.44%
-0.33
시간 외 거래:
9.14
전일 마감가:
$9.47
열려 있는:
$9.36
하루 거래량:
460.18K
Relative Volume:
2.72
시가총액:
$468.78M
수익:
-
순이익/손실:
$-76.41M
주가수익비율:
-4.57
EPS:
-2
순현금흐름:
$-64.56M
1주 성능:
-18.76%
1개월 성능:
-22.91%
6개월 성능:
+24.48%
1년 성능:
+11.73%
Aura Biosciences Inc Stock (AURA) Company Profile
명칭
Aura Biosciences Inc
전화
(617)500-8864
주소
80 GUEST STREET, BOSTON
AURA을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
AURA | 9.14 | 468.78M | 0 | -76.41M | -64.56M | -2.00 |
VRTX | 467.12 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 762.38 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 567.35 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 232.27 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 101.83 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2023-07-27 | 개시 | Scotiabank | Sector Outperform |
2023-04-17 | 재개 | BTIG Research | Buy |
2022-07-19 | 개시 | JMP Securities | Mkt Outperform |
Aura Biosciences Inc 주식(AURA)의 최신 뉴스
HC Wainwright Forecasts Higher Earnings for Aura Biosciences - Defense World
Aura Biosciences, Inc. (NASDAQ:AURA) Short Interest Up 7.6% in October - MarketBeat
Aura Biosciences’ (AURA) Buy Rating Reiterated at HC Wainwright - Defense World
What is Leerink Partnrs’ Estimate for AURA FY2024 Earnings? - Defense World
Research Analysts Set Expectations for AURA FY2024 Earnings - MarketBeat
Citadel Advisors LLC Reduces Stake in Aura Biosciences Inc - GuruFocus.com
Brokerages Set Aura Biosciences, Inc. (NASDAQ:AURA) Target Price at $23.00 - Defense World
HC Wainwright Reaffirms Buy Rating for Aura Biosciences (NASDAQ:AURA) - MarketBeat
Aura Biosciences Reports Q3 Financial Results - TipRanks
Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study - MSN
Aura Biosciences : Reports Third Quarter 2024 Financial Results and Business Highlights Form 8 K - Marketscreener.com
Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewswire
Aura Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Aura Biosciences, Inc. (NASDAQ:AURA) Receives Average Rating of "Buy" from Analysts - MarketBeat
Aura Biosciences, Inc. (NASDAQ:AURA) Short Interest Update - Defense World
One Aura Biosciences Insider Raised Stake By 232% In Previous Year - Yahoo Finance
Short Interest in Aura Biosciences, Inc. (NASDAQ:AURA) Decreases By 8.7% - MarketBeat
Aura Biosciences, Inc. (NASDAQ:AURA) Insider Sells $98,808.00 in Stock - MarketBeat
Aura Biosciences VP sells shares worth $5,938 By Investing.com - Investing.com Australia
Aura Biosciences CEO Elisabet de los Pinos sells $98,787 in stock By Investing.com - Investing.com South Africa
Aura Biosciences CEO Elisabet de los Pinos sells $98,787 in stock - Investing.com
Aura Biosciences VP sells shares worth $5,938 - Investing.com
Don't Ignore The Insider Selling In Aura Biosciences - Simply Wall St
Aura Biosciences (NASDAQ:AURA) Stock Price Down 4.9% After Insider Selling - Defense World
Aura Biosciences CFO Julie Feder sells shares worth $302,361 - Investing.com India
Aura Biosciences (NASDAQ:AURA) Trading Down 4.9% on Insider Selling - MarketBeat
Aura Biosciences, Inc. (NASDAQ:AURA) CFO Sells $302,325.93 in Stock - MarketBeat
Aura Biosciences: 2 Positive Bel-Sar Data Releases Brings Shareholder Value - Seeking Alpha
Aura Biosciences, Inc. (NASDAQ:AURA) Receives $23.00 Average Price Target from Analysts - Defense World
Long Term Trading Analysis for (AURA) - Stock Traders Daily
Aura Biosciences (NASDAQ:AURA) PT Raised to $22.00 at HC Wainwright - Defense World
Aura Biosciences stock hits 52-week high at $12.38 By Investing.com - Investing.com Australia
Aura Biosciences CEO sells $300,838 in stock By Investing.com - Investing.com Australia
Aura Biosciences reports promising early trial results - Investing.com India
Insider Selling: Aura Biosciences, Inc. (NASDAQ:AURA) Insider Sells 24,992 Shares of Stock - MarketBeat
Aura Biosciences CEO sells $300,838 in stock - Investing.com
Aura Biosciences, Inc. (NASDAQ:AURA) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Aura Biosciences' Shares Touch 52-Week High on Positive Cancer Drug Data - MarketWatch
Aura Biosciences (NASDAQ:AURA) Hits New 12-Month High After Analyst Upgrade - MarketBeat
Aura Biosciences stock hits 52-week high at $12.38 - Investing.com
Aura Biosciences stock maintains Buy rating on promising trial results By Investing.com - Investing.com Canada
Aura Biosciences' Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade Disease - Benzinga
Aura Biosciences (NASDAQ:AURA) Price Target Increased to $23.00 by Analysts at Scotiabank - MarketBeat
Aura Biosciences stock price target up 5%, H.C. Wainwright rates Buy after virtual oncology event - Investing.com Canada
Aura Biosciences Shares Surge After-Hour On Positive Clinical Trial Results - Stocks Telegraph
Multiple Clinical Complete Responses Demonstrated Following - GlobeNewswire
Aura Biosciences Reports Positive Phase 1 Trial Results - TipRanks
Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial - The Manila Times
Aura Biosciences reports promising early trial results By Investing.com - Investing.com UK
Aura Biosciences Inc (AURA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):